Table 2.
Subjects tested positive for immunoglobulin (Ig)A and/or IgG against the rotavirus particles (a) and the four synthetic peptides (b)
| (a) | Antibody positivity to TLPs | Antibody positivity to DLPs | ||||||
|---|---|---|---|---|---|---|---|---|
| Study groups (no.) | IgA | IgG | IgA+IgG | Total positive (%) | IgA | IgG | IgA+IgG | Total positive (%) |
| CD (118) | 12 | 4 | 6 | 22 (18·5%) | 5 | 13 | 9 | 27 (23%) |
| POT (46) | – | – | – | – | 2 | – | 1 | 3 (6·5%) |
| GD (32) | – | – | 1 | 1 (3%) | 5 | 1 | 12 | 18 (56%) |
| HC (107) | 3 | 9 | 5 | 17 (16%) | – | 3 | 9 | 12 (11%) |
| HA (107) | 14 | 14 | 1 | 29 (27%) | 6 | 36 | 6 | 48 (45%) |
| (b) | Antibody positivity to pCP | Antibody positivity to ptTG | Antibody positivity to pVP7 | Antibody positivity to pCTRL | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study Groups (N°) | IgA | IgG | IgA+IgG | Total positive (%) | IgA | IgG | IgA+IgG | Total positive (%) | IgA | IgG | IgA+IgG | Total positive (%) | IgA | IgG | IgA+IgG | Total positive (%) |
| CD (118) | 22 | – | 6 | 28 (24%) | 14 | – | 2 | 16 (13.5%) | 34 | – | – | 34 (29%) | 34 | – | 1 | 35 (30%) |
| POT (46) | 4 | 2 | – | 6 (13%) | 1 | – | – | 1 (2%) | 4 | – | – | 4 (9%) | 2 | – | – | 2 (4%) |
| GD (32) | 1 | – | – | 1 (3%) | – | – | – | – | 1 | – | – | 1 (3%) | 1 | – | – | 1 (3%) |
| HC (107) | 3 | 1 | – | 4 (4%) | 1 | 1 | 1 | 3 (3%) | 2 | 1 | 1 | 4 (4%) | 1 | – | 1 | 2 (2%) |
| HA (107) | 14 | 30 | 4 | 48 (45%) | 4 | 32 | 10 | 46 (43%) | 2 | 48 | 16 | 66 (62%) | 4 | 52 | – | 56 (52%) |
pCP = dodecamer peptide; ptTG = transglutaminase‐derived peptide; pVP7 = VP7‐derived peptide; pCTRL = irrelevant control peptide; TLP = triple‐layered rotavirus (RV) particles; DLP = double‐layered RV particles; CD = coeliac disease; POT = potential CD; GD = gastrointestinal disease; HC = healthy controls; HA = healthy adults.